Compound Summary
Levosulpiride
Compound Information
Levosulpiride
Compound Name: | Levosulpiride |
Compound CID: | 688272 |
Synonyms: | Levosulpiride 23672-07-3 (S)-(-)-sulpiride (-)-Sulpiride Levopraid More... |
Iupac Name: | N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-methoxy-5-sulfamoylbenzamide |
InChI: | InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1 |
InChIKey: | BGRJTUBHPOOWDU-NSHDSACASA-N |
Canonical Smiles: | CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC |
Isomeric Smiles: | CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC |
Molecular Weight: | 341.4 |
Molecular Formula: | C15H23N3O4S |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
Levosulpiride
Molecular Weight: | 341.4 |
Molecular Formula: | C15H23N3O4S |
Hydrogen Bond Donor Count: | 2 |
Hydrogen Bond Acceptor Count: | 6 |
Rotatable Bond Count: | 6 |
Heavy Atom Count: | 23 |
Complexity: | 505 |
Synonyms
Levosulpiride
| Levosulpiride | Levosulpiride |
|---|---|
Levosulpiride |
23672-07-3 |
(S)-(-)-sulpiride |
(-)-Sulpiride |
Levopraid |
S-(-)-Sulpiride |
Levosulpirida |
Levosulpiridum |
(S)-sulpiride |
RV-12309 |
UNII-JTG7R315LK |
N-{(2S)-1-ethylpyrrolidin-2-ylmethyl}-2-methoxy-5-sulfamoylbenzamide |
Levosulpiride INN |
(S)-(-)-5-aminosulfonyl-N-(1-ethyl-2-pyrrolidinyl)methyl-2-methoxybenzamide |
JTG7R315LK |
CHEBI:64119 |
(S)-(-)-N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide |
N-(2S)-1-ethylpyrrolidin-2-ylmethyl-2-methoxy-5-sulfamoylbenzamide |
S-(-)-N-(1-Ethyl-2-pyrrolidinomethyl)-2-methoxy-5-sulfamoylebenzamide |
MFCD00055220 |
Levosulpiride (INN) |
NCGC00024853-05 |
(-)-N-(((S)-1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide |
Levosulpiridum INN-Latin |
DSSTox_CID_22583 |
DSSTox_RID_80052 |
DSSTox_GSID_42583 |
Levosulpirida INN-Spanish |
Nexipride |
SMR000466366 |
CAS-23672-07-3 |
(S)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-methoxy-5-sulfamoylbenzamide |
SULPIRIDE,(+) |
C15H23N3O4S |
Levogastrol |
Sulpiride-l |
Sulpiride-S |
Sulpiride l-form |
N-((2S)-1-ethylpyrrolidin-2-yl)methyl(6-methoxy-3-sulfamoylphenyl)carboxamid e |
Levopraid (TN) |
CAS-15676-16-1 |
Tocris-0895 |
Sulpiride L-(-) |
Biomol-NT_000030 |
Levosulpiride (Levogastrol) |
Lopac0_001089 |
SCHEMBL70112 |
GTPL958 |
MLS000759490 |
MLS001424014 |
BPBio1_001221 |
CHEMBL267044 |
(S)-N-(1-Ethylpyrrolidin-2-yl)methyl-2-methoxy-5-sulfamoylbenzamide |
DTXSID0042583 |
BDBM81774 |
ZINC57008 |
HMS2051A08 |
HMS2089E04 |
HMS2232P10 |
HMS3263I20 |
HMS3266P14 |
HMS3411D20 |
HMS3675D20 |
HMS3884H07 |
HY-B1059 |
Tox21_110933 |
Tox21_501089 |
PDSP1_000516 |
PDSP1_000620 |
PDSP1_001649 |
PDSP2_000514 |
PDSP2_000616 |
s2104 |
SBB058180 |
(S)-5-Aminosulfonyl-N-(1-ethyl-2-pyrrolidinyl)methyl-2-methoxybenzamide |
AKOS007930553 |
AKOS015897363 |
Tox21_110933_1 |
AC-6821 |
BCP9000853 |
CCG-100847 |
CS-4581 |
KS-5103 |
LP01089 |
NC00097 |
SDCCGSBI-0051059.P002 |
Benzamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoyl-, S-(-)- |
NCGC00015966-10 |
NCGC00016718-01 |
NCGC00024853-01 |
NCGC00024853-02 |
NCGC00024853-03 |
NCGC00024853-04 |
NCGC00024853-06 |
NCGC00024853-09 |
NCGC00024853-11 |
NCGC00261774-01 |
BL166176 |
BCP0726000072 |
CAS_15676-16-1 |
(S)-(-)-Sulpiride, >=98% (titration) |
EU-0101089 |
I0821 |
ST50319539 |
SW197477-2 |
D07312 |
H11356 |
S 7771 |
AB00639965-06 |
AB00639965-08 |
AB00639965_09 |
672L073 |
A816834 |
SR-01000076136 |
SR-01000597436 |
J-015181 |
Q1452256 |
SR-01000076136-2 |
SR-01000597436-1 |
BRD-K51671335-001-01-5 |
BRD-K51671335-001-04-9 |
(S)-(-)-Sulpiride, VETRANAL(TM), analytical standard |
UNII-7MNE9M8287 component BGRJTUBHPOOWDU-NSHDSACASA-N |
N-(1-ethylpyrrolidin-2-yl)methyl-5-methoxy-2-sulfamoyl-benzamide |
(-)-5-Aminosulfonyl-N-(1-ethyl-2-pyrrolidinyl)methyl-2-methoxybenzamide |
Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-, (S)- (9CI) |
Benzamide, 5-(aminosulfonyl)-N-(2S)-1-ethyl-2-pyrrolidinylmethyl-2-methoxy- |
o-ANISAMIDE, N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-5-SULFAMOYL-, (S)-(-)- |
5-HT6 Serotonin Receptor from rat, recombinant, expressed in HEK 293 cells, membrane suspension |
Experimental Data
Levosulpiride
| Species | Dose | Unit | Control(Avg days) | Treatment(Avg days) | Avg/Med Lifespan Change(%) | Control(Max days) | Treatment(Max days) | Max Lifespan Change(%) | Significant | Strain | Gender | PubMed | Avg/Med Lifespan Change tab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33.000000000000000 | umol/L | 2.000000000000000 | NS | N2 | 24134630 | Inactive | ||||||
| Caenorhabditis elegans | 10.000000000000000 | umol/L | 17.370000000000000 | 16.960000000000000 | -2.362000000000000 | NS | N2 | 33008901 | Inactive | ||||
| Caenorhabditis elegans | 100.000000000000000 | umol/L | 15.860000000000000 | 16.610000000000000 | 4.709000000000000 | NS | N2 | 33008901 | Inactive | ||||
| Drosophila melanogaster | 200.000000000000000 | umol/L | 43.170000000000000 | 45.290000000000000 | 4.905000000000000 | NS | MALES | 33008901 | Inactive | ||||
| Drosophila melanogaster | 20.000000000000000 | umol/L | 44.630000000000000 | 45.000000000000000 | 0.835300000000000 | NS | FEMALES | 33008901 | Inactive |
Experimental Data Visualization
Levosulpiride
Statistics Data
Levosulpiride
| Species | Avg/Med Lifespan Change(%) | Max Lifespan Change(%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | 4.709000000000000 | 2 | 3 | |
| Drosophila melanogaster | 4.905000000000000 | 1 | 2 |
Statistics Data Visualization
Levosulpiride
